glp-1 therapy protein intake optimization Dietary by patients taking and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs Optimizing GLP-1 therapies for obesity
Description
FDA-approved semaglutide products (Ozempic, Wegovy, Rybelsus) are commercially available
A key feature of the consensus is its endorsement of shared decision-making, taking into account patient goals, preferences, access, and affordability
Solutions for a healthier, happier you.
Public Citizen contends that Novo Nordisk and Eli Lilly's obesity drugs are straining budgets so much that generics should be authorized.
